Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 6Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 21Gastrointestinal 6Thoracic 5Genitourinary 5Lymphoid 4Tumor-Agnostic 3CNS 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Recurrent Ovarian High Grade Serous Adenocarcinoma 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 96pembrolizumab 63Cisplatin 62Cyclophosphamide 44Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 24olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × abemaciclib × Gynecologic × Clear all
NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
42 enrolled
Gynecologic

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡